Claims granted for rapid s screening against targets inside cells
Perth, Australia: April 11, 22011 – Australian drug discovery company Phylogica Ltd (ASX:PYC) today announced that a key UUS patent has been granted for the Company’s peptide drug discovery platform.
The patent (US 77,919,610 B2) describes innovative methods of screening molecular libraries against interactions between disease-associated proteins inside cell s. Such high-value ‘intracellular targets’ play a key role in multiple disease as such as cancer and inflammation, but are difficult to hit with conventional drugs. The patent was filed by the prestigious Fox Chase Cancer Centre in the USAA and is already exclusively licensed to Phylogica.
In granting the patent, the US Patent and Trademark Office recognised the innovation and technical advancement of the invention. The patented technology is faster and more amenable to automation than current techniques and will enable Phylogica to rapidly identify Phylomer drug candidates against challenging disease targets in living cells.
Phylogica’s CEO, Dr Paul Watt, said: “We are delighted by the grant of this patent, which is an important addition to our intellectual property portfolio. As more is known about the molecular mechanisms inside cells that cause disease, the pharmaceutical industry is increasingly interested in sourcing drug candidates that can target these intracellular disease pathways.
Traditionally, protein interactions inside cells have been very hard to block, but this patented screening technology is ideally suited for rapid identification of Phylomer® drug candidates against such targets. The combination of this proprietary technology, together with our dominant intellectual property around Phylomer® libraries, further differentiates Phylogica as the partner of choice for peptide drug discovery.”
Download this document
